ra 642 has been researched along with dipyridamole in 7 studies
| Studies (ra 642) | Trials (ra 642) | Recent Studies (post-2010) (ra 642) | Studies (dipyridamole) | Trials (dipyridamole) | Recent Studies (post-2010) (dipyridamole) |
|---|---|---|---|---|---|
| 20 | 0 | 0 | 7,826 | 881 | 632 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrasco, T; De La Cruz, JP; Sánchez de la Cuesta, F; Smith-Agreda, JM; Villalobos, MA | 1 |
| Carrasco, T; de la Cruz, JP; Ortega, G; Sanchez de la Cuesta, F | 1 |
| De la Cruz, JP; Garcia-Campos, J; Moreno, A; Sanchez de la Cuesta, F; Sintas, A | 1 |
| de la Cruz, JP; Moron, D; Sanchez de la Cuesta, F | 1 |
| de la Cruz, JP; García-Campos, J; Mérida, F; Moreno, A; Sánchez de la Cuesta, F | 1 |
| Benítez, A; De la Cruz, JP; Gonzalez-Correa, JA; Olveira, C; Sánchez de la Cuesta, F | 1 |
| De La Cruz, JP; García Campos, J; Mérida, F; Moreno, A; Sánchez de la Cuesta, F | 1 |
7 other study(ies) available for ra 642 and dipyridamole
| Article | Year |
|---|---|
The pyrimido-pyrimidine derivative RA-642 protects from brain injury in a combined model of permanent focal ischemia and global ischemia reperfusion.
Topics: Animals; Brain; Dipyridamole; Disease Models, Animal; Ischemic Attack, Transient; Lipid Peroxidation; Male; Mitochondria; Mopidamol; Oxidation-Reduction; Pyrimidines; Rats; Rats, Wistar; Reperfusion Injury; Tetrazolium Salts | 1992 |
Inhibition of ferrous-induced lipid peroxidation by pyrimido-pyrimidine derivatives in human liver membranes.
Topics: Animals; Ascorbic Acid; Cardiotonic Agents; Cell Membrane; Dipyridamole; Ferrous Compounds; Humans; Kinetics; Lipid Peroxidation; Liver; Malondialdehyde; Mopidamol; Pyrimidines; Rats; Species Specificity; Vitamin E | 1992 |
Dipyridamole and RA-642 inhibit the production of superoxide anion and free radical damage to rat lens.
Topics: Animals; Cardiotonic Agents; Dipyridamole; Free Radicals; Lens, Crystalline; Lipid Peroxidation; Male; Pyrimidines; Rats; Rats, Inbred Strains; Superoxides | 1991 |
Antiplatelet effect of the pyrimido-pyrimidinic derivative RA-642.
Topics: Adenosine; Cardiotonic Agents; Dipyridamole; Dose-Response Relationship, Drug; Humans; Male; Mopidamol; Platelet Aggregation Inhibitors; Pyrimidines; Theophylline | 1991 |
The pyrimido-pyrimidine derivatives, dipyridamole and RA-642, reduce opacification of crystalline lens in diabetic rats.
Topics: Animals; Blood Glucose; Cardiotonic Agents; Cataract; Diabetes Mellitus, Experimental; Dipyridamole; Lens, Crystalline; Lipid Peroxidation; Male; Malondialdehyde; Mopidamol; Pyrimidines; Rats; Rats, Wistar; Superoxides | 1994 |
Inhibition of ferrous-induced lipid peroxidation by dipyridamole, RA-642 and mopidamol in human lung tissue.
Topics: Adult; Aged; Animals; Antioxidants; Dipyridamole; Female; Ferrous Compounds; Humans; In Vitro Techniques; Lipid Peroxidation; Lung; Male; Malondialdehyde; Middle Aged; Mopidamol; Pyrimidines; Rats; Rats, Wistar; Thiobarbituric Acid Reactive Substances; Vitamin E | 1996 |
The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Dipyridamole; Epoprostenol; Male; Mopidamol; Neovascularization, Pathologic; Platelet Aggregation Inhibitors; Pyrimidines; Rats; Rats, Wistar; Thromboxanes | 1996 |